Levels of circulating tumor DNA (ctDNA) detected in a blood test are correlated with the size of ovarian cancers and can predict a patient’s response to treatment or time to disease progression… …read more
Giving birth to an infant with a major congenital anomaly was associated with a small but statistically significant increased risk for maternal death, a population-based cohort study has found. Medscape Medical News …read more
The U.S. Food and Drug Administration has granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer. …read more
Ensuring patients are healthy for surgery and have access to specialists should take priority over timing. …read more